Coronary artery disease. Atherosclerotic heart disease
Conditions
Interventions
Intervention 1: 2. group B: intermittent furosemide therapy
these patients received 0.2 mg/kg furosemide during CABG only in the case of decreased urinary excretion rate below the determined level in the study. Intervention 2: 1. group A: intra-prime furosemid
these patients received 0.3-0.4 mg/kg furosemide in the prime solution. Intervention 3: 3. group C: the control group.
Treatment - Drugs
Placebo
2. group B: intermittent furosemide therapy
these patients received 0.2 mg/kg furosemide during CABG only in the case of decreased urinary excretion rate below the determined level in the study
1. group A: intra-prime furosemide therapy
these patients received 0.3-0.4 mg/kg furosemide in the prime solution
3. group C: the control group
Sponsors
Vice chancellor for research, Shahid Rajaei Heart Center
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age 40-75; elective CABG with CPB; constant surgeon; informed written consent; Exclusion criteria: old age above 75 years; emergency surgery; high risk surgery; ischemic heart disease; diabetes mellitus; diabetic ketoacidosis; non-ketonic hyperosmolar diabetic coma; acute renal failure; chronic kidney disease causing serum Cr>2mg/dL; glomerulonephritis; hepatic failure causing liver function test failure (> 3 times than normal); off pump CABG; any unwanted complication in the operation period; re-starting CPB after weaning from bypass; pulmonary artery pressure >30 before operation; ejection fraction<30%; re-operation in the postoperative period; congestive heart failure; thyroid disorders; acute infections; stroke; pregnancy; hospital admission in the recent 3 months;
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative serum markers of renal function including Glomerular Filtration Rate (GFR). Timepoint: Preoperative levels and also early postoperative period (mainly 24 hours). Method of measurement: level of serum markers; then using the Cockcroft-Gault formula. | — |
Secondary
| Measure | Time frame |
|---|---|
| Acid-base and electrolytes of the plasma. Timepoint: before the intervention and 24 hours after intervention. Method of measurement: serum levels of markers. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Dabbagh
Anesthesiology Research Center
Outcome results
None listed